Gilead Brings HIV Prevention to the 27th Annual Latin GRAMMY Awards®
Gilead Sciences Inc GILD
News
A Run of FDA Target Dates Fills the Biotech Calendar From Late November to Year End
Gabelli Releases Agenda for 8th Annual Healthcare Symposium
New Data Show Twice-Yearly Lenacapavir Achieved Nearly Twice the One-Year Persistence of Daily Oral F/TDF in HIV Prevention
Positive Phase 3 IDEAL Study Results Further Support Livdelzi®’s (Seladelpar) Impact on Achieving ALP Normalization Goals in Second-Line Treatment Across a Broad Population of People Living with Primary Biliary Cholangitis (PBC)
Stocks Surged Across the Board Today, and Biotech Brought Its Own Earnings Story
Gilead and Kite Advance Leadership With New Data Across Pipeline and Portfolio at ASH 2026
Gilead to Present Late-Breaking Clinical Data and Real-World Evidence at HIV Glasgow
Gilead Sciences to Present at Upcoming Fourth Quarter 2026 Investor Conferences
The big winners of the tech wreck are biopharma stocks
Gilead Sciences Announces Third Quarter 2026 Financial Results
Gilead Acquires Oral IL-23R Inhibitor Program for $1.275 Billion in Cash
Gilead to Acquire Investigational Oral IL-23R Inhibitor HCXT-2001, Strengthening Its Inflammation Pipeline in IBD
Gilead to Present New Data on Treatment Response and Long-Term Management of Rare Liver Diseases at The Liver Meeting® 2026
Gilead to Present New Data Across HIV and Emerging Antiviral Research at IDWeek 2026
Big pharma stocks close near all-time highs as tech selloff pushes investors toward safer bets
Gilead Sciences to Release Third Quarter 2026 Financial Results on Thursday, October 29, 2026
Gilead Sciences On Track for Record High Close — Data Talk
Vir Biotechnology Shares Jump on Gilead Cancer Collaboration
Gilead Accelerates Global Access Planning for Investigational Once-Yearly Lenacapavir for HIV Prevention
United States